참고문헌
- Azzoli CG, Temin S, Aliff T, et al (2011). Focused update of 2009 American society of clinical oncology American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 29, 3825-31. https://doi.org/10.1200/JCO.2010.34.2774
- Birchard KR, Hoang JK, Herndon JE Jr, et al (2009). Early changes in tumor size in patients treated for advanced stage non-small cell lung cancer do not correlate with survival. Cancer, 115, 581-6. https://doi.org/10.1002/cncr.24060
- Cerfolio RJ, Ojha B, Bryant AS, et al (2004). The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg, 78, 1017-23. https://doi.org/10.1016/j.athoracsur.2004.02.067
- De Geus-Oei LF, van der Heijden HF, Visser EP, et al (2007). Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. Nucl Med, 48, 1592-98. https://doi.org/10.2967/jnumed.107.043414
- Ding Q, Cheng X, Yang L, et al (2014). PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis, 6, 677-83.
- Dwamena BA, Sonnad SS, Angobaldo JO, et al (1999). Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology, 213, 530-36. https://doi.org/10.1148/radiology.213.2.r99nv46530
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Hasbek Z, Yucel B, Salk I, et al (2014). Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/CT on survival in lung cancer patients. Asian Pac J Cancer Prev, 15, 4085-9. https://doi.org/10.7314/APJCP.2014.15.9.4085
-
Hoekstra CJ, Stroobants SG, Smit EF, et al (2005). Prognostic relevance of response evaluation using [
$^{18}F$ ]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 23, 8362-70. https://doi.org/10.1200/JCO.2005.01.1189 - Jemal A, Bray F, Center MM (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
-
Lee DH, Kim SK, Lee HY, et al (2009). Early prediction of response to first-line therapy using integrated
$^{18}F$ -FDG-PET/CT for patients with advanced/metastatic non-small cell lung cancer. Thorac Oncol, 4, 816-21. https://doi.org/10.1097/JTO.0b013e3181a99fde - Mac Manus MP, Hicks RJ, Matthews JP, et al (2003). Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 21, 1285-92. https://doi.org/10.1200/JCO.2003.07.054
- Martin J, Ginsberg RJ, Venkatraman ES, et al (2002). Long-term results of combined-modality therapy in resectable nonsmall-cell lung cancer. J Clin Oncol, 20, 1989-95. https://doi.org/10.1200/JCO.2002.08.092
- Miranda E, Bianchi P, Destro A, et al (2013). Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 119, 266-76. https://doi.org/10.1002/cncr.27722
-
Nahmias C, Hanna WT, Wahl LM, et al (2007). Time course of early response to chemotherapy in non-small cell lung cancer patients with
$^{18}F$ -FDG PET/CT. J Nucl Med, 48, 744-51. https://doi.org/10.2967/jnumed.106.038513 -
Novello S, Vavala T, Levra MG, et al (2013). Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [
$^{18}F$ ]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Clin Lung Cancer, 14, 230-7. https://doi.org/10.1016/j.cllc.2012.10.004 - Sekine I, Tamura T, Kunitoh H, et al (1999). Progressive disease rate as a surrogate endpoint of phase II trials fornon-smallcell lung cancer. Ann Oncol, 10, 731-3. https://doi.org/10.1023/A:1008303921033
- Suzuki C, Jacobsson H, Hatschek T, et al (2008). Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics, 28, 329-44. https://doi.org/10.1148/rg.282075068
- Vansteenkiste J, Fischer BM, Dooms C, et al. (2004). Positronemission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol, 5, 531-40. https://doi.org/10.1016/S1470-2045(04)01564-5
- Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009). From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med, 50, 122-50. https://doi.org/10.2967/jnumed.108.057307
- Weber WA, Figlin R (2007). Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med, 48, 36-44.
- Weber WA, Petersen V, Schmidt B, et al (2003). Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 21, 2651-7. https://doi.org/10.1200/JCO.2003.12.004
피인용 문헌
- Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations vol.17, pp.8, 2016, https://doi.org/10.1080/15384047.2016.1195049
- Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer vol.43, pp.11, 2016, https://doi.org/10.1007/s00259-016-3420-7
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments vol.44, pp.S1, 2017, https://doi.org/10.1007/s00259-017-3687-3